



DENISE GOLGHER

Biotechnology specialist, Ph.D.

+55 21 3550 3758

denise.golgher@lickslegal.com

PRACTICE AREAS

- Patents
- Life Sciences

LANGUAGES

- Portuguese
- English

BIOGRAPHY

Denise Golgher joined Licks Attorneys' Rio de Janeiro office as a Biotechnology specialist in 2015. She has over 20 years' experience working with Cell Biology, Immunology and Biotechnology. Her extensive experience includes studies and analysis of emerging technologies in human health and business development. In addition, Ms. Golgher is well versed in the biotechnology sector in Brazil, having coordinated a study in 2007 and worked as a consultant in the Brazil Biotech map of 2011. Since 2003, she consults for companies, academics and venture capitalists in Brazil and abroad in biotechnology-based businesses. Denise studied Business Management at Dom Cabral Foundation (Brazil), which ranks as the best business school in Latin America.

EDUCATION

- Post-doctoral Degree in Tumour Immunology, University of Oxford (laboratory later relocated to Southampton), 2003;
- PhD in Cell Biology, Johns Hopkins University, 1999;
- MSc in Biochemistry, University of Sao Paulo (USP), 1992;
- BSc in Biology, Federal University of Minas Gerais (UFMG), 1989.

PUBLICATIONS

- [A Amazônia em destaque: Uma oportunidade para a biotecnologia no Brasil](#), Decisor Brasil, 2023;
- [Bacteriophages and the Pressing Problem of Antibiotic Resistance](#), Genetic Engineering & Biotechnology News, 2023;
- [The Amazon in the Limelight: An Opportunity for Biotech in Brazil](#), Genetic Engineering & Biotechnology News, 2023;
- [Biomedical R&D in Brazil: who owns IP rights?](#), The Legal 500, 2022;
- [Biomedical Innovation in Brazil: an update](#), Bioengineering, 2022;
- [Golgher D, Rodrigues R, Olmos M and Castro AC. 2018. Breaking through asphalt. The private sector takes the lead in biomedical innovation in Brazil;](#)

- Golgher D; Rodrigues, R . The Business of Immuno-Oncology; *Genetic Engineering and Biotechnology News*, 01 fev. 2016;
- Golgher D Rodrigues R and Massafra RC Biosimilars in Brazil: Developments in 2015 and Business Perspectives *Journal of Commercial Biotechnology* (2015) 21(4), 44–50;
- Torres-Freire, C; Callil, V, Golgher, D. 2015. Human Health Biotechnology in Brazil: Can we advance? *Journal of Commercial Biotechnology*. 21:20-30;
- Zalcberg I and Golgher D. 2015 Molecular Genetics of Glioblastomas: Defining sub-types and understanding biology. *Neuroimaging Clin N Am*. 25(1):97-103;
- Golgher D, Elliott, T, Howarth, M. 2003. Processing and presentation of glycoproteins in the MHC class I and II antigen presentation pathways In: *Immunobiology of Carbohydrates* ed.: Landes Bioscience;
- Golgher D, Jones E, Powrie F, Elliott T, Gallimore A. 2002. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. *Eur J Immunol*. 32(11):3267-75;
- Golgher D, Korangy F, Gao B, Gorski K, Jaffee E, Edidin M,; Pardoll DM, Elliott T. 2001. An immunodominant MHC class II-restricted tumor antigen is conformation dependent and binds to the endoplasmic reticulum chaperone, calreticulin. *J Immunol*. 167(1):147-55.